Industry news that matters to you.  Learn more

Karmanos Cancer Institute Uses Definiens Tissue Studio for Biomarker Development

Definiens, the number one Health Image Intelligence company, today announced that the Barbara Ann Karmanos Cancer Institute in Detroit is using Definiens image analysis software in a new approach to cancer diagnosis and biomarker development. The Karmanos Cancer Institute is applying Definiens Tissue Studio 2.0TM, the newest version of the company’s leading image analysis software for digital pathology, to automate tissue section and microarray analysis. Led by Gerold Bepler, M.D., Ph.D., president and CEO of the Karmanos Cancer Institute, the research team will replace tedious manual analysis processes with automated image analysis to more reliably develop biomarkers that facilitate patient stratification models for personalized medicine applications.

Revalesio Partners with Predictive Biomarker Sciences to Assess Potential Cancer Treatment

Revalesio Corporation announced today that it has contracted with Predictive Biomarker Sciences (PBS-Bio) to conduct studies related to the use of Revalesio’s novel anti-inflammatory therapeutic in treating cancer.

To jump-start drug development, PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work and identifies biomarkers that can help predict which patients will respond to treatment.

Caprion Proteomics Identifies Promising New Candidate Biomarkers to Predict Response to Hepatitis C Treatment

Caprion Proteomics announced today that it has identified promising candidate protein biomarker panels that appear to predict patient responsiveness to treatment for hepatitis C.

The study employed Caprion’s proprietary CellCarta mass spectrometry-based proteomics discovery platform to measure and compare the expression levels of thousands of proteins contained in blood samples collected from patients infected with the hepatitis C virus (HCV), in order to discover predictive biomarkers of sustained response to hepatitis C therapy.

Panel Calls for Biomarkers in Routine Clinical AD Diagnosis

Clinicians should try to incorporate biomarker data in their diagnosis of patients with Alzheimer’s disease or conditions potentially leading to it, an ad hoc expert panel recommended.

Levels of beta-amyloid or tau proteins in cerebrospinal fluid (CSF), or data from MRI or PET scans using amyloid-specific tracers, should be part of the differential diagnosis of Alzheimer-related disorders, according to two dozen members of the International Working Group for New Research Criteria for the Diagnosis of Alzheimer’s Disease.

Novel Biomarker May Predict Response to New VEGF Receptor Inhibitor

Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.